BNTX Stock Recent News

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (BNTX -6.58%). Investors were concerned about the latest top-level appointment in public health, plus an analyst became a bit more bearish about the company's future.

BioNTech maintains strong cash reserves (€15.85B) despite widening losses as COVID revenues decline and R&D expenses increase. BNT327 (PD-L1/VEGF-A bispecific) advances to Phase 3 trials, but shares dropped after competitor's interim data disappointed investors. Increased regulatory scrutiny under Kennedy's HHS creates uncertainty for mRNA technologies, prompting a downgrade from Buy to Hold.

BioNTech SE  BNTX on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02.

BioNTech SE (NASDAQ:BNTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder & Chief Executive Officer Özlem Türeci - Co-Founder & Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Daina Graybosch - Leerink Partners Cory Kasimov - Evercore Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Evan Seigerman - BMO Capital Markets Yaron Werber - TD Cowen Mohit Bansal - Wells Fargo Harry Gillis - Berenberg John Newman - Canaccord Genuity Operator Welcome to BioNTech's First Quarter 2025 Earnings Call. I would like to hand the call over to Michael Horowicz, Director, Investor Relations.

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1 , and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech's combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates (“ADCs”) Development and commercial preparation for a 2025/2026 season variant-adapted COVID-19 vaccine First quarter 2025 revenues of €0.2 billion 2 , net loss of €0.4 billion and basic and diluted loss per share of €1.73 ($1.823) Maintained strong financial position with €15.9 billion in cash, cash equivalents and security investments as of March 31, 20254 Full year 2025 financial guidance confirmed Conference call and webcast scheduled for May 5, 2025, at 8:00 a.m. EDT (2:00 p.m.

German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, 2025. He will join BioNTech from Novartis AG's global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June 30, 2025.

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTech (BNTX -15.40%) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading.

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research (“AACR”) Annual Meeting held in Chicago, Illinois from April 25-30, 2025. The oral and poster presentations underline both the progress of BioNTech's advanced priority oncology programs as well as the execution of the Company's combination strategy in oncology, with first data to be presented for the combination of the PD-L1xVEGF-A bispecific antibody candidate BNT3271 plus antibody-drug conjugates (“ADCs”).